



an Open Access Journal by MDPI

## State-of-the-Art Cancer Biology, Biodiagnostics and Therapeutics in Japan

Guest Editors:

**Prof. Dr. Hideshi Ishii**

Department of Frontier Science  
for Cancer and Chemotherapy,  
Osaka University, Suita, Japan

**Dr. Takaaki Hirotsu**

Center of Medical Innovation and  
Translational Research, Osaka  
University Graduate School of  
Medicine, Suita, Yamadaoka 2-2,  
Osaka 565-0871, Japan

Deadline for manuscript  
submissions:

**closed (31 January 2023)**

### Message from the Guest Editors

Nearly one in six deaths, worldwide, is due to cancer, which is the leading cause of death. In recent decades, tremendous efforts, all around the world, have been undertaken to understand the mechanisms of cancer, provide precise and sensitive diagnostic solutions and develop effective therapeutics.

Japan cultivates a fine technological and scientific excellence and is at the forefront of cancer research.

In recognition of the vibrant scientific community in Japan, from academia to the private sector, we are seeking submissions of original research articles or reviews presenting impactful advances in the development of cancer biology, biodiagnostics and therapeutics, in Japan, on one or more of, but not limited to, the following topics:

- Cancer biology;
- Molecular mechanisms of cancers;
- Cancer epigenetics;
- Mechanism of resistance to conventional therapies;
- Cancer biomarkers;
- Early detection of cancers;
- Clinical investigations;
- Diagnostics of cancers;
- Novel therapeutics;
- Novel paradigms in the diagnosis and treatment of cancers.



[mdpi.com/si/114766](https://mdpi.com/si/114766)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI